Medical treatment for biochemical relapse after radiotherapy

Ray, 2006, PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis, Int J Radiat Oncol Biol Phys, 64, 1140, 10.1016/j.ijrobp.2005.07.006 Thames, 2003, Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995, Int J Radiat Oncol Biol Phys, 15, 929, 10.1016/S0360-3016(03)00631-X Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 Boorjian, 2011, Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence, Eur Urol, 59, 893, 10.1016/j.eururo.2011.02.026 Antonarakis, 2011, Long-term overall survival and metastasis-free survival for men with prostate specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database, BJU Int, 108, 378, 10.1111/j.1464-410X.2010.09878.x Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 D’Amico, 2003, Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era, J Clin Oncol, 21, 2163, 10.1200/JCO.2003.01.075 Patel, 1997, Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and logslope prostate specific antigen, J Urol, 158, 1441, 10.1016/S0022-5347(01)64238-1 Kupelian, 2002, Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era, Int J Radiat Oncol Biol Phys, 52, 704, 10.1016/S0360-3016(01)02778-X Zelefsky, 2005, Outcome predictors for the increasing PSA state after definitive external beam radiotherapy for prostate cancer, J Clin Oncol, 23, 826, 10.1200/JCO.2005.02.111 D’Amico, 2003, Surrogate end-point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy, J Natl Cancer Inst, 95, 1376, 10.1093/jnci/djg043 Kim-Sing, 2004, Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database, Int J Radiat Oncol Biol Phys, 60, 463, 10.1016/j.ijrobp.2004.03.004 Pollack, 1994, Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer, Cancer, 74, 670, 10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO;2-8 Sartor, 1997, Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy, Int J Radiat Oncol Biol Phys, 38, 941, 10.1016/S0360-3016(97)00082-5 Lee, 2005, Prostate specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy, Int J Radiat Oncol Biol Phys, 63, 456, 10.1016/j.ijrobp.2005.03.008 Buyyounouski, 2008, Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy, Int J Radiat Oncol Biol Phys, 70, 59, 10.1016/j.ijrobp.2007.05.047 Ceci, 2014, 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT, Eur J Nucl Med Mol Imaging, 41, 878, 10.1007/s00259-013-2655-9 Giovacchini, 2014, 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy, J Nucl Med, 55, 233, 10.2967/jnumed.113.123380 Agarwal, 2008, Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes, Cancer, 112, 307, 10.1002/cncr.23161 Shipley, 2002, Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10, Int J Radiat Oncol Biol Phys, 54, 1302, 10.1016/S0360-3016(02)03052-3 Taylor, 2009, Review of major adverse effects of androgen deprivation therapy in men with prostate cancer, Cancer, 115, 2388, 10.1002/cncr.24283 The Medical Research Council Prostate Cancer Working Party Investigators Group, 1997, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial, Br J Urol, 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x Studer, 2004, Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trail SAKK 08/88, J Clin Oncol, 22, 4109, 10.1200/JCO.2004.11.514 Studer, 2006, Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trail 30891, J Clin Oncol, 24, 1868, 10.1200/JCO.2005.04.7423 Schroder, 2009, Eur Urol, 55, 14, 10.1016/j.eururo.2008.09.008 Loblaw, 2007, Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 25, 1596, 10.1200/JCO.2006.10.1949 Moul, 2004, Early versus delayed hormonal treatment therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy, J Urol, 171, 1141, 10.1097/01.ju.0000113794.34810.d0 Lu-Yao, 2008, Survival following primary androgen deprivation therapy among men with localized prostate cancer, JAMA, 300, 173, 10.1001/jama.300.2.173 Faria, 2006, No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy, Urology, 67, 142, 10.1016/j.urology.2005.07.019 Souhami, 2010, Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31, Int J Radiat Oncol Biol Phys, 78, 1301, 10.1016/j.ijrobp.2009.10.007 Mydin, 2013, Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy – a secondary analysis of Irish clinical oncology research group 97-01, Int J Radiat Oncol Biol Phys, 85, 101, 10.1016/j.ijrobp.2012.03.001 Pinover, 2003, Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy, Cancer, 97, 1127, 10.1002/cncr.11166 Tenenholz, 2007, Survival benefit for early hormone ablation in biochemically recurrent prostate cancer, Urol Oncol, 25, 101, 10.1016/j.urolonc.2006.03.002 Stewart, 2006, Prostate specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate specific antigen failure, J Clin Oncol, 23, 6556, 10.1200/JCO.2005.20.966 Nguyen, 2010, Comorbidity, body mass index, and age and the risk of nonprostate cancer-specific mortality after a postradiation prostate specific antigen recurrence, Cancer, 116, 610, 10.1002/cncr.24818 Lofters, 2002, PSA-itis: knowledge of serum prostate specific antigen and other causes of anxiety in man with metastatic prostate cancer, J Urol, 168, 2516, 10.1016/S0022-5347(05)64180-8 Dale, 2009, Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study, J Clin Oncol, 27, 1557, 10.1200/JCO.2008.18.5850 Mottet, 2013, Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?, Eur Urol, 63, 121, 10.1016/j.eururo.2012.08.004 Crook, 2012, Intermittent androgen suppression for rising PSA level after radiotherapy, N Engl J Med, 367, 895, 10.1056/NEJMoa1201546 Calais da Silva, 2009, Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group, Eur Urol, 55, 1269, 10.1016/j.eururo.2009.02.016 Yu, 2010, Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation, J Clin Oncol, 28, 2668, 10.1200/JCO.2009.25.1330 Schroder, 2012, Eur Urol, 63, 779, 10.1016/j.eururo.2012.11.006 Monk, 2011, Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782, Cancer, 118, 4139, 10.1002/cncr.26732 Smith, 2006, Celecoxib versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy, J Clin Oncol, 24, 2723, 10.1200/JCO.2005.03.7804 Schroder, 2005, Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement, Eur Urol, 48, 922, 10.1016/j.eururo.2005.08.005 Paller, 2013, Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions, Clin Adv Hematol Oncol, 11, 14 Taplin, 2006, Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate specific antigen progression after definitive local therapy for prostate cancer, J Clin Oncol, 24, 5408, 10.1200/JCO.2006.06.6589 Moussaid, 2013, Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma, Cancer Radiother, 17, 259, 10.1016/j.canrad.2013.01.019 2014